Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-06-26
2007-06-26
Lewis, Patrick (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S047000, C514S912000, C514S915000, C536S026800
Reexamination Certificate
active
11114957
ABSTRACT:
A method and preparation for enhancing drainage of lacrimal system in a subject in need of such treatment is disclosed. The method comprises administering to the ocular surfaces of the subject a purinergic receptor agonist such as uridine 5′-triphosphate (UTP), dinucleotides, cytidine 5′-triphosphate (CTP), adenosine 5′-triphosphate (ATP), or their therapeutically useful analogs and derivatives, in an amount effective to stimulate tear fluid secretion and enhance drainage of the lacrimal system. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include: topical administration via a liquid, gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form.
REFERENCES:
patent: 4380239 (1983-04-01), Crawford
patent: 4658816 (1987-04-01), Ector, Jr.
patent: 4753945 (1988-06-01), Gilbard et al.
patent: 4868154 (1989-09-01), Gilbard et al.
patent: 4921485 (1990-05-01), Griffiths
patent: 5021043 (1991-06-01), Becker
patent: 5062831 (1991-11-01), Griffiths
patent: 5169386 (1992-12-01), Becker
patent: 5292498 (1994-03-01), Boucher, Jr.
patent: 5345948 (1994-09-01), O'Donnell, Jr.
patent: 5900407 (1999-05-01), Yerxa et al.
patent: 23 30 902 (1975-03-01), None
patent: WO 97 35591 (1997-10-01), None
patent: WO 98 03177 (1998-01-01), None
patent: WO 98 03182 (1998-01-01), None
patent: WO 98 03182 (1998-01-01), None
Al-Hussein, H., et al., “Silastic Intubation in Congenital Nasolacrimal Duct Obstruction: A Study of 129 Eyes”Ophthalmic Plastic&Reconstructive Surgery9(1):32-37 (1993).
Bartley, G.B., “Acquired Lacrimal Drainage Obstruction: An Etiologic Classification System, Case Reports, and a Review of the Literature. Part 1”Ophthalmic Plastic Reconstructive Surgery, 8(4):237-242 (1992).
Blicker, J.A., et al., “Lacrimal Sac, Conjunctival, and Nasal Culture Results in Dacryocystorhinostomy Patients,”Ophthalmic Plastic&Reconstructive Surgery, 9(1):43-46 (1993).
Conway, S.T., “Evaluation and Management of “Functional” Nasolacrimal Blockage: Results of a Survey of the American Society of Ophthalmic Plastic and Reconstructive Surgery,”Ophthalmic Plastic&Reconstructive Surgery, 10(3):185-188 (1994).
Dartt, D.A., et al., “Vasoactive Intestinal Peptide-Stimulated Glycoconjugate Secretion from Conjunctival Goblet Cells,”Exp. Eye Res., 63:27-34 (1996).
Dortzbach, R.K., et al., “Silicone Intubation for Obstruction of the Nasolacrimal Duct in Children,”American Journal of Ophthalmology. 94(5):585-590 (1982).
Foster, J.A., et al., “Results of Dacryoscintigraphy in Massage of the Congenitally Blocked Nasolacrimal Duct,”Ophthalmic Plastic and Reconstructive Surgery 12(1):32-37 (1996).
Gilbard, J.P., “Dry Eye: Pharmacological Approaches, Effects, and Progress,”CLAO Journal, 22(2):141-145 (1996).
Gilbard, J.P., “Treatment of Keratoconjunctivitis Sicca in Rabbits With 3-Isobutyl-1-Methylxanthine,”Arch. Opthalmol,.112:1614-1616 (1994).
Gilbard, J.P., et al., “Stimulation of Tear Secretion and Treatment of Dry-Eye Disease With 3-Isobutyl-1-methylxanthine,”Arch. Opthalmol. 109(5):672-676 (1991).
Gilbard, J.P., et al., “Stimulation of Tear Secreation by Topical Agents That Increase Cyclic Nucleotide Levels,”Investigative Opthalmology&Visual Science, 31(7):1381-1388 (1990).
Gilbard, J.P., et al., “Osmolarity of Tear Microvolumes in Keratoconjunctivitis Sicca,”Archives of Ophthalmology 96(4):677-681 (1978).
Gromada, J., et al., “Role of protein kinase C in the regulation of inositol phosphate production and Ca2+mobilization evoked by ATP and acetylcholine in rat lacrimal acini,”Eur. J. Physiol. 429:578-586 (1995).
Grynkiewicz, G. et al., “A New Generation of Ca2+Indicators with Greatly Improved Fluorescence Properties,” J. Biol. Chem. 260(6):3440-3450 (1985).
Hyde, K.J., et al., “Epidemic Keratoconjunctivitis and Lacrimal Excretory System Obstruction,”Opthamol.,95(10):1447-1449 (1988).
Inatomi, T., et al., “Expression of Secretory Mucin Genes by Human Conjunctival Epithelia,”Inv. Opthamol.&Vis. Sci. 37(8):1684-1692 (1996).
Kassoff, Jr., et al., “Early office-based vs late hospital-based nasolacrimal duct probing. A clinical decision analysis”Arch. Opthamol 113(9):1168-1171 (1995).
Lemp, M.A., “Is the Dry Eye Contact Lens Wearer at Risk? Yes,”Comea 9(1):S48-S50 (1990).
Linberg, J.V., et al., “Primary Acquired Nasolacrimal Duct Obstructon A Clinicopathologic Report and Biopsy Technique,”Opthamol., 93(8):1055-1063 (1986).
Mason, S., et al., “Regulation of transepithelial ion transport and intracellular calcium by extracellular ATP in human normal and cystic fibrosis airway epithelium,”Br. J. Pharmacol. 103:1649-56 (1991).
Mauriello, Jr., J.A., et al., “Clinicopathologic Study of Lacrimal Sac and Nasal Mucosa in 44 Patients with Complete Acquired Nasolacrimal Duct Obstruction,”Opthalmic Plastic&Reconstructive Surgery, 8(1):13-21 (1992).
Moss, A. and Parsons, V.,National Center for Health Statistics, 1986:66-7, DHHS Publication No. (PHS) 86-1588 (1985).
Ng, K.E., et al., “The action of a water-solable arbindimide on adenosine-5'-polyphosphates,”Nucleic Acid Res., 15:3573-3580 (1987).
Olivier, K., et al., “Acute Safety and Effects on Mucociliary Clearance of Aerosolized Uridine 5'-Triphosphate ± Amiloridie in Normal Human Adults”,Am. J. Respr. Crit. Care Med. 154: 217-23 (1996).
Rapaport, E., et al., “HeLa cell DNA polymerase α is tightly associated with tryptophanyl-tRNA synthetase and diadenosine 5', 5'-P1, P4-tetraphosphate binding activities,”Proc. Natl. Acad. Sci.,78:838 (1981).
Sasaki, T. et al., “Extracellular ATP activates receptor-operated cation channels in mouse lacrimal acinar cells to promote calcium influx in the absence of phosphoinositide metabolism”,FEBS 264(1):130-124 (1990).
Sasaki, T., et al., “The ATP-induced inward current in mouse lacrimal acinar cells is potentiated by isoprenaline and GTP,”J. Physiol. 447:103-118 (1992).
Shermetaro, C., et al., “Adult nasolacrimal duct obstruction,”JAOA 94(3):229-232 (1994).
Tarbet, K.J., et al., “Extemal Dacryocystorhinostomy Surgical Success, Patient Satisfaction, and Ecomonic Cost”,Opthalmol.,102(7):1065-1070 (1995).
Vincent, P., “Cationic channels sensitive to extracellular ATP in rat lacrimal cells,”J. Physiol. 449:313-331 (1992).
Visscher, J., et al., “Selective cleavage of pyrophosphate linkages,”Nucleic Acids Research 20(21):5749-5752.
Vovsi, B. N. et al., “Importance of hydrodynamic indices for pathogenic treatment of penetrating wounds of the eye”, XP002035486 see abstract.
Young, J.D.H., et al., “Congenital nasolacrimal duct obstruction in the second year of life: a multicentre trial of management,”Eye, 10:485-491 (1996).
Jacobus Karla M.
Pendergast William
Rideout Janet L.
Yerxa Benjamin R.
Howrey LLP
Inspire Pharmaceuticals Inc.
Kung Viola T.
Lewis Patrick
LandOfFree
Method of enhancing drainage of lacrimal system with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of enhancing drainage of lacrimal system with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of enhancing drainage of lacrimal system with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3883862